Eagle Pharmaceuticals Inc (EGRX) - Total Assets
Based on the latest financial reports, Eagle Pharmaceuticals Inc (EGRX) holds total assets worth $404.82 Million USD as of June 2023. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Eagle Pharmaceuticals Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Eagle Pharmaceuticals Inc - Total Assets Trend (2012–2022)
This chart illustrates how Eagle Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See EGRX book value for net asset value and shareholders' equity analysis.
Eagle Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2022)
Eagle Pharmaceuticals Inc's total assets of $404.82 Million consist of 46.5% current assets and 53.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.6% |
| Accounts Receivable | $73.44 Million | 18.1% |
| Inventory | $47.79 Million | 11.8% |
| Property, Plant & Equipment | $1.17 Million | 0.3% |
| Intangible Assets | $118.33 Million | 29.1% |
| Goodwill | $45.03 Million | 11.1% |
Asset Composition Trend (2012–2022)
This chart illustrates how Eagle Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Eagle Pharmaceuticals Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eagle Pharmaceuticals Inc's current assets represent 46.5% of total assets in 2022, a decrease from 93.9% in 2012.
- Cash Position: Cash and equivalents constituted 13.6% of total assets in 2022, down from 53.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 29.1% of total assets.
Eagle Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Eagle Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩745.80 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥11.80 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥3.12 Billion |
Eagle Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.16 | 1.78 | 5.58 |
| Quick Ratio | 1.67 | 1.25 | 5.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $100.62 Million | $85.49 Million | $162.36 Million |
Eagle Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Eagle Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.16 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 60.1% |
| Total Assets | $406.16 Million |
| Market Capitalization | $3.29 Million USD |
Valuation Analysis
Below Book Valuation: The market values Eagle Pharmaceuticals Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Eagle Pharmaceuticals Inc's assets grew by 60.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eagle Pharmaceuticals Inc (2012–2022)
The table below shows the annual total assets of Eagle Pharmaceuticals Inc from 2012 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $406.16 Million | +60.07% |
| 2021-12-31 | $253.73 Million | +0.21% |
| 2020-12-31 | $253.19 Million | -0.54% |
| 2019-12-31 | $254.55 Million | +6.69% |
| 2018-12-31 | $238.60 Million | -11.65% |
| 2017-12-31 | $270.06 Million | +26.45% |
| 2016-12-31 | $213.57 Million | +71.40% |
| 2015-12-31 | $124.61 Million | +133.29% |
| 2014-12-31 | $53.41 Million | +195.05% |
| 2013-12-31 | $18.10 Million | +91.80% |
| 2012-12-31 | $9.44 Million | -- |
About Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non… Read more